JP2017502941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502941A5 JP2017502941A5 JP2016538536A JP2016538536A JP2017502941A5 JP 2017502941 A5 JP2017502941 A5 JP 2017502941A5 JP 2016538536 A JP2016538536 A JP 2016538536A JP 2016538536 A JP2016538536 A JP 2016538536A JP 2017502941 A5 JP2017502941 A5 JP 2017502941A5
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- drug substance
- weight
- pharmaceutical formulation
- total weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915606P | 2013-12-13 | 2013-12-13 | |
| US61/915,606 | 2013-12-13 | ||
| PCT/IB2014/066820 WO2015087283A1 (en) | 2013-12-13 | 2014-12-11 | Pharmaceutical dosage forms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019082147A Division JP6804585B2 (ja) | 2013-12-13 | 2019-04-23 | 医薬剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502941A JP2017502941A (ja) | 2017-01-26 |
| JP2017502941A5 true JP2017502941A5 (https=) | 2018-01-25 |
| JP6522619B2 JP6522619B2 (ja) | 2019-05-29 |
Family
ID=52146563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538536A Active JP6522619B2 (ja) | 2013-12-13 | 2014-12-11 | 医薬剤形 |
| JP2019082147A Active JP6804585B2 (ja) | 2013-12-13 | 2019-04-23 | 医薬剤形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019082147A Active JP6804585B2 (ja) | 2013-12-13 | 2019-04-23 | 医薬剤形 |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US10278969B2 (https=) |
| EP (2) | EP3597179B1 (https=) |
| JP (2) | JP6522619B2 (https=) |
| KR (1) | KR102349893B1 (https=) |
| CN (2) | CN116942629A (https=) |
| AR (1) | AR098716A1 (https=) |
| AU (1) | AU2014362999B2 (https=) |
| CA (1) | CA2930055C (https=) |
| CL (1) | CL2016001436A1 (https=) |
| CY (1) | CY1122063T1 (https=) |
| DK (1) | DK3079667T3 (https=) |
| EA (1) | EA036288B1 (https=) |
| EC (1) | ECSP16060194A (https=) |
| ES (1) | ES2745983T3 (https=) |
| HR (1) | HRP20191691T1 (https=) |
| HU (1) | HUE045156T2 (https=) |
| IL (1) | IL245705B (https=) |
| LT (1) | LT3079667T (https=) |
| MA (1) | MA39175A1 (https=) |
| MX (1) | MX2016007652A (https=) |
| MY (1) | MY194303A (https=) |
| NZ (2) | NZ719865A (https=) |
| PE (1) | PE20160851A1 (https=) |
| PH (1) | PH12016501039B1 (https=) |
| PL (1) | PL3079667T3 (https=) |
| PT (1) | PT3079667T (https=) |
| RS (1) | RS59270B1 (https=) |
| SG (1) | SG10202104627UA (https=) |
| SI (1) | SI3079667T1 (https=) |
| TN (1) | TN2016000207A1 (https=) |
| TW (2) | TWI721938B (https=) |
| WO (1) | WO2015087283A1 (https=) |
| ZA (1) | ZA201603064B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ719865A (en) | 2013-12-13 | 2022-07-29 | Novartis Ag | A pharmaceutical dosage form produced from the wet granulation of 3-(2,6-dichloro-3,5- dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methylurea |
| MA41611A (fr) * | 2015-02-23 | 2018-01-02 | Omthera Pharmaceuticals Inc | Préparations en milli-capsules comprenant des acides gras polyinsaturés libres |
| EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
| CA3202267A1 (en) * | 2020-12-18 | 2022-06-23 | Riccardo Panicucci | Methods of treating achondroplasia |
| WO2022194941A1 (en) * | 2021-03-17 | 2022-09-22 | Actelion Pharmaceuticals Ltd | Pharmaceutical dosage system |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| BRPI0620408B8 (pt) | 2005-12-21 | 2021-05-25 | Novartis Ag | derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica |
| FR2910813B1 (fr) * | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | Nouvelle utilisation therapeutique pour le traitement des leucemies |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| RU2014103250A (ru) | 2011-07-01 | 2015-08-10 | Новартис Аг | Комбинированная терапия |
| EP3019491A4 (en) | 2013-07-09 | 2016-12-21 | Dana Farber Cancer Inst Inc | KINASEHEMMER FOR THE TREATMENT OF DISEASES |
| NZ719865A (en) | 2013-12-13 | 2022-07-29 | Novartis Ag | A pharmaceutical dosage form produced from the wet granulation of 3-(2,6-dichloro-3,5- dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methylurea |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| EP3273959A1 (en) | 2015-03-25 | 2018-01-31 | Novartis Ag | Pharmaceutical combinations |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
-
2014
- 2014-12-11 NZ NZ719865A patent/NZ719865A/en unknown
- 2014-12-11 LT LTEP14819084.6T patent/LT3079667T/lt unknown
- 2014-12-11 CN CN202310950714.8A patent/CN116942629A/zh active Pending
- 2014-12-11 AU AU2014362999A patent/AU2014362999B2/en active Active
- 2014-12-11 MY MYPI2016701712A patent/MY194303A/en unknown
- 2014-12-11 EP EP19181217.1A patent/EP3597179B1/en active Active
- 2014-12-11 AR ARP140104615A patent/AR098716A1/es not_active Application Discontinuation
- 2014-12-11 EP EP14819084.6A patent/EP3079667B1/en active Active
- 2014-12-11 PL PL14819084T patent/PL3079667T3/pl unknown
- 2014-12-11 PH PH1/2016/501039A patent/PH12016501039B1/en unknown
- 2014-12-11 SI SI201431315T patent/SI3079667T1/sl unknown
- 2014-12-11 MX MX2016007652A patent/MX2016007652A/es active IP Right Grant
- 2014-12-11 CA CA2930055A patent/CA2930055C/en active Active
- 2014-12-11 NZ NZ760002A patent/NZ760002A/en unknown
- 2014-12-11 TN TN2016000207A patent/TN2016000207A1/en unknown
- 2014-12-11 PE PE2016000773A patent/PE20160851A1/es unknown
- 2014-12-11 PT PT148190846T patent/PT3079667T/pt unknown
- 2014-12-11 EA EA201691231A patent/EA036288B1/ru unknown
- 2014-12-11 HR HRP20191691TT patent/HRP20191691T1/hr unknown
- 2014-12-11 DK DK14819084.6T patent/DK3079667T3/da active
- 2014-12-11 RS RSP20191178 patent/RS59270B1/sr unknown
- 2014-12-11 WO PCT/IB2014/066820 patent/WO2015087283A1/en not_active Ceased
- 2014-12-11 HU HUE14819084A patent/HUE045156T2/hu unknown
- 2014-12-11 SG SG10202104627UA patent/SG10202104627UA/en unknown
- 2014-12-11 CN CN201480067964.6A patent/CN105813635A/zh active Pending
- 2014-12-11 KR KR1020167015239A patent/KR102349893B1/ko active Active
- 2014-12-11 ES ES14819084T patent/ES2745983T3/es active Active
- 2014-12-11 JP JP2016538536A patent/JP6522619B2/ja active Active
- 2014-12-11 US US15/102,378 patent/US10278969B2/en active Active
- 2014-12-11 MA MA39175A patent/MA39175A1/fr unknown
- 2014-12-12 TW TW103143546A patent/TWI721938B/zh active
- 2014-12-12 TW TW109136485A patent/TWI800759B/zh active
-
2016
- 2016-05-06 ZA ZA2016/03064A patent/ZA201603064B/en unknown
- 2016-05-18 IL IL245705A patent/IL245705B/en active IP Right Grant
- 2016-06-10 CL CL2016001436A patent/CL2016001436A1/es unknown
- 2016-07-13 EC ECIEPI201660194A patent/ECSP16060194A/es unknown
-
2019
- 2019-03-26 US US16/364,727 patent/US11160804B2/en active Active
- 2019-04-23 JP JP2019082147A patent/JP6804585B2/ja active Active
- 2019-09-23 CY CY20191100999T patent/CY1122063T1/el unknown
-
2021
- 2021-09-29 US US17/489,382 patent/US20220265651A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI856111B (zh) | 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法 | |
| JP2017502941A5 (https=) | ||
| KR101977785B1 (ko) | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법 | |
| JP2007091758A5 (https=) | ||
| JP6320371B2 (ja) | エンテカビルの医薬組成物および製造方法 | |
| CN104661649A (zh) | 包含替格瑞洛的固态口服医药制剂 | |
| JP2016536285A (ja) | アムロジピン及びバルサルタンを含む安定な医薬組成物 | |
| JP2013147470A (ja) | 口腔内崩壊錠 | |
| JP5614445B2 (ja) | 経口投与用粒子状医薬組成物 | |
| JP2011500811A5 (https=) | ||
| KR101171375B1 (ko) | 난용성 약물을 함유하는 경구 제형 | |
| KR102349893B1 (ko) | 제약 투여 형태 | |
| CN102846573B (zh) | 水飞蓟宾双层缓释片及其制备方法 | |
| JP2013544272A5 (https=) | ||
| JP2017520619A5 (https=) | ||
| JP6379043B2 (ja) | カンデサルタンシレキセチル含有医薬組成物 | |
| KR20100046216A (ko) | 칸데사르탄의 약학 조성물 | |
| JP2016124861A (ja) | オルメサルタンメドキソミル含有口腔内崩壊錠 | |
| CN104000821B (zh) | 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法 | |
| JP5755382B2 (ja) | 口腔内崩壊錠 | |
| CN101152155A (zh) | 盐酸伊伐布雷定固体药物组合物及其制备方法 | |
| CN112057427A (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
| CN113768889B (zh) | 一种含西洛他唑的药物组合物及其制备方法 | |
| WO2014122671A2 (en) | Solid oral compositions of saxagliptin | |
| JP6344678B2 (ja) | テルミサルタン含有製剤及びその製造方法 |